Equity · Healthcare
CAI
NASDAQCaris Life Sciences (CAI)
The line runs 26.12 USD on 24 August through 17.62 USD on 20 November, on a scale from 10 to 40. Days the market did not trade hold the previous close, flat.
- Market cap
- 5.1B USD
- P/E (TTM)
- 2.1
- Revenue, year to Dec 2025
- 812.0M USD
- EPS, diluted, year to Dec 2025
- −3.22 USD
- 52-week range
- 14.56 USD – 36.16 USD
- Avg volume
- 277.4K
- Mentions, 30 days
- 1
as of Nov 20, 2026
Have Caris Life Sciences (CAI) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Caris Life Sciences insiders reported 4 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 15 May 2026.
Form 4, 90 days to 22 Nov 2026, newest reported trade 22 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 22 Sep 2026 | Denton John RusselSee Remarks | Sell | 7,500 | 239K USD |
| 17 Sep 2026 | Brille Brian JSee Remarks | Sell | 400,000 | 12.1M USD |
| 04 Sep 2026 | Spetzler David BaxleyPresident | Sell | 119,212 | 3.0M USD |
| 03 Sep 2026 | Spetzler David BaxleyPresident | Sell | 478,000 | 11.9M USD |
| Sold | 4 open-market sales | 1,004,712 | $27.20M |
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Sep 2026 | Brille Brian JSee Remarks | Option exercise | 400,000 | 976K USD |
| 04 Sep 2026 | Spetzler David BaxleyPresident | Option exercise | 250,000 | 610K USD |
| 03 Sep 2026 | Spetzler David BaxleyPresident | Option exercise | 1,000,000 | 2.4M USD |
Which funds hold Caris Life Sciences (CAI)?
8 of the 45 institutional funds we track reported a Caris Life Sciences position for the quarter ended 30 Sep 2026 — a combined 587.7M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Added | 8,210,498 | 251.5M USD | +13,791.8% |
| D. E. Shaw & Co. | Added | 7,218,295 | 221.1M USD | +3,424.2% |
| Millennium Management | Trimmed | 1,565,225 | 47.9M USD | −28.9% |
| Renaissance Technologies | Held (±25%) | 656,500 | 20.1M USD | +15.6% |
| Citadel Advisors | Added | 653,413 | 20.0M USD | +119.4% |
| Two Sigma Investments | Added | 558,872 | 17.1M USD | +1,456.7% |
| Tudor Investment Corp | Added | 162,974 | 5.0M USD | +62.4% |
| Balyasny Asset Management | New position | 160,959 | 4.9M USD | |
| Coatue Management | Exited | |||
| Duquesne Family Office | Exited |
What has been filed or recorded for Caris Life Sciences (CAI)?
The filings we hold for Caris Life Sciences, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 21 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 21 Oct 2026 | Fails to deliver | Shares failed to deliver | 166,598 shares | 5.2M USD notional · 0.058% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 138,306 shares | 4.1M USD notional · 0.048% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,461 shares | 94K USD notional · 0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.05 USD | Revenue $275M |
| 30 Sep 2026 | Financials | Total assets | 1.3B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 639.5M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.00 USD | Revenue $264M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.00 USD | Revenue $216M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.22 USD | Revenue $812M |
| 31 Dec 2025 | Financials | Revenue | 812.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −68.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −3.22 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.08 USD | Revenue $217M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −7.97 USD | Revenue $181M |
| 31 Mar 2025 | Quarterly earnings | Q1 2026 reported | EPS −3.57 USD | Revenue $121M |
| 31 Dec 2024 | Annual report | FY 2025 reported | EPS −10.66 USD | Revenue $412M |
What is Reddit saying about Caris Life Sciences (CAI)?
Reddit mentioned CAI 1 times in the 30 days to 22 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 100% read bullish, 0% bearish and 0% neither. Reddit data updated 22 November 2026.
30-day window, Method
How do Reddit mentions of Caris Life Sciences (CAI) compare with its price?
Share ↗
Which subreddits are talking about Caris Life Sciences (CAI)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 100% | 1 | +0.39 |
What do people ask about Caris Life Sciences (CAI)?
What did Caris Life Sciences shares close at?17.62
Caris Life Sciences closed at 17.62 USD on 20 Nov 2026, down 6.53% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Caris Life Sciences’ market cap?5.1B
Caris Life Sciences is worth 5.1B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Caris Life Sciences’ P/E ratio?2.1
Caris Life Sciences has a price-to-earnings ratio of 2.1, as of 20 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Caris Life Sciences’ revenue?812.0M
Caris Life Sciences reported revenue of 812.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Caris Life Sciences insiders bought or sold shares recently?4 sales
In the 90 days to 22 Nov 2026, Caris Life Sciences insiders reported 4 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 15 May 2026. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Caris Life Sciences?8 of 45
8 of the 45 funds we track reported a Caris Life Sciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, D. E. Shaw & Co. and Millennium Management. See Funds
When did Caris Life Sciences last report earnings?0.05
Caris Life Sciences last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.05 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Caris Life Sciences?1 mentions
Caris Life Sciences was mentioned 1 times in the last 7 days across the finance subreddits we track, and 1 times over the trailing 30 days. Of the 1 mentions scored for sentiment, 100% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words